Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc (NQ: LTRN )

3.840 +0.080 (+2.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,504
Open 3.770
Bid (Size) 3.570 (13)
Ask (Size) 3.850 (1)
Prev. Close 3.760
Today's Range 3.740 - 3.850
52wk Range 2.380 - 6.200
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
From Lantern Pharma Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga

Performance

YTD
-37.86%
-37.86%
1 Month
+37.14%
+37.14%
3 Month
-14.29%
-14.29%
6 Month
-28.89%
-28.89%
1 Year
-24.26%
-24.26%

More News

Read More
Lantern Pharma: Q3 Earnings Insights
Via Benzinga
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
A Preview Of Lantern Pharma's Earnings
Via Benzinga
Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
The 7 Most Undervalued AI Penny Stocks to Buy: October 2023
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma
From Lantern Pharma
Via Business Wire
Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas
From Lantern Pharma Inc.
Via Business Wire
The 3 Most Undervalued Machine Learning Stocks to Buy in September 2023
Via InvestorPlace
Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual Meeting
From Lantern Pharma Inc.
Via Business Wire
3 AI Stocks That Still Trade Under $10 Per Share
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors
From Lantern Pharma Inc.
Via Business Wire
The 3 Most Undervalued Machine Learning Stocks to Buy Now: August 2023
Via InvestorPlace
8 Best Artificial Intelligence Stocks Under $10
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
The 3 Most Undervalued AI Penny Stocks to Buy Now: August 2023
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
3 AI Penny Stocks With the Potential to Make Your Financial Dreams Come True
Via InvestorPlace
3 AI Stocks You’ll Regret Not Buying Soon
Via InvestorPlace
7 AI Stocks to Buy Under $5 in August 2023
Via InvestorPlace
RedChip Launches 'Small Stocks, Big Money' Podcast
Via ACCESSWIRE
Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.